Literature DB >> 12732243

Differential regulation of corticosteroid receptors by monoamine neurotransmitters and antidepressant drugs in primary hippocampal culture.

M Lai1, J A McCormick, K E Chapman, P A T Kelly, J R Seckl, J L W Yau.   

Abstract

Hyperactivity of the hypothalamic-pituitary-adrenal axis is a characteristic feature of depressive illness. The centrally located corticosteroid receptors, the glucocorticoid and mineralocorticoid receptors, are thought to be important modulators of this axis and changes in the levels of these receptors, particularly in the hippocampus, may underlie the hyperactivity observed. Various antidepressant drugs increase hippocampal mineralocorticoid and glucocorticoid receptor levels in vivo. These effects are thought to be mediated via alterations in monoaminergic neurotransmission. We examined whether serotonin (5HT) and noradrenaline (NA) have direct effects on glucocorticoid receptor and mineralocorticoid receptor expression in primary hippocampal neurones, and whether antidepressants also exert direct effects on target neurones. Exposure of hippocampal cells to 5HT for 4 days increased both glucocorticoid and mineralocorticoid receptor mRNA and protein expression. The induction of mineralocorticoid receptor mRNA was completely blocked by the 5HT(7) receptor antagonist SB 269970. In contrast glucocorticoid receptor induction was insensitive to the 5HT(7) receptor, whilst studies with the 5HT(1A) receptor agonist 8-hydroxy-2-(di-n-proplamino) tetralin hydrochloride and the 5HT(1A) receptor antagonist N-[2-[4-2-[O-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexane carboxamide trihydrochloride (WAY 100635) suggest a partial role for 5HT(1A) receptors in hippocampal glucocorticoid receptor regulation. Treatment with NA for 4 days also increased glucocorticoid receptor expression but had no effect on mineralocorticoid receptor expression. This was blocked by propanolol suggesting action via beta-adrenergic receptors. Similarly to NA, fluoxetine and amitriptyline also selectively increased glucocorticoid receptor mRNA and protein levels over this time course. However, glucocorticoid receptor induction by fluoxetine or amitriptyline was not blocked by WAY 100635 or propanolol. These results show that 5HT, NA and antidepressants act directly but via distinct mechanisms on hippocampal neurones to regulate mineralocorticoid and glucocorticoid receptor expression. Thusly, manipulation of neurotransmitter or antidepressant levels in the brain may aid in reversing hypothalamic-pituitary-adrenal axis hyperactivity by restoring hippocampal corticosteroid receptor balance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732243     DOI: 10.1016/s0306-4522(03)00038-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  19 in total

1.  Serotonergic effects on feeding, but not hypothalamus-pituitary-adrenal secretion, are altered in ovine pregnancy.

Authors:  Melissa Lingis; Elaine Richards; Dana Perrone; Maureen Keller-Wood
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-28       Impact factor: 4.310

2.  Outside the brain: an inside view on transgenic animal and stem cell-based models to examine neuronal serotonin-dependent regulation of HPA axis-controlled events during development and adult stages.

Authors:  Jonas Waider; Janina Ziegler; Thorsten Lau
Journal:  Stem Cell Investig       Date:  2016-12-19

Review 3.  The glucocorticoid receptor: pivot of depression and of antidepressant treatment?

Authors:  Christoph Anacker; Patricia A Zunszain; Livia A Carvalho; Carmine M Pariante
Journal:  Psychoneuroendocrinology       Date:  2011-04       Impact factor: 4.905

4.  Regulation of mineralocorticoid receptor expression during neuronal differentiation of murine embryonic stem cells.

Authors:  Mathilde Munier; Geri Meduri; Say Viengchareun; Philippe Leclerc; Damien Le Menuet; Marc Lombès
Journal:  Endocrinology       Date:  2010-03-05       Impact factor: 4.736

5.  The methylated-DNA binding protein MBD2 enhances NGFI-A (egr-1)-mediated transcriptional activation of the glucocorticoid receptor.

Authors:  Ian C G Weaver; Ian C Hellstrom; Shelley E Brown; Stephen D Andrews; Sergiy Dymov; Josie Diorio; Tie-Yuan Zhang; Moshe Szyf; Michael J Meaney
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-09-26       Impact factor: 6.237

6.  Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients.

Authors:  Andreas Menke; Janine Arloth; Benno Pütz; Peter Weber; Torsten Klengel; Divya Mehta; Mariya Gonik; Monika Rex-Haffner; Jennifer Rubel; Manfred Uhr; Susanne Lucae; Jan M Deussing; Bertram Müller-Myhsok; Florian Holsboer; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2012-01-11       Impact factor: 7.853

7.  Clomipramine treatment and repeated restraint stress alter parameters of oxidative stress in brain regions of male rats.

Authors:  Rodrigo de Souza Balk; Jessika Cristina Bridi; Rafael de Lima Portella; Nelson Rodrigues Carvalho; Fernando Dobrachinski; Michele Hinerasky da Silva; Guilherme Pires Amaral; Glaecir Roseni Mundstock Dias; Nilda de Vargas Barbosa; Felix Alexandre Antunes Soares
Journal:  Neurochem Res       Date:  2010-08-08       Impact factor: 3.996

8.  Neuronal nitric oxide synthase is an endogenous negative regulator of glucocorticoid receptor in the hippocampus.

Authors:  Meng-ying Liu; Li-Juan Zhu; Qi-Gang Zhou
Journal:  Neurol Sci       Date:  2012-10-14       Impact factor: 3.307

9.  Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters.

Authors:  Carmine M Pariante; Richard B Kim; Andrew Makoff; Robert W Kerwin
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

10.  Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala.

Authors:  Elizabeth I Flandreau; Chase H Bourke; Kerry J Ressler; Wylie W Vale; Charles B Nemeroff; Michael J Owens
Journal:  Psychoneuroendocrinology       Date:  2012-12-23       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.